Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Erlin1em1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Erlin1em1/Cya

Common Name
Erlin1-KO
Product ID
S-KO-05943
Backgroud
C57BL/6JCya
Strain ID
KOCMP-226144-Erlin1-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Erlin1-KO Mouse (Catalog S-KO-05943) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Erlin1-KO
Strain ID
KOCMP-226144-Erlin1-B6J-VA
Gene Name
Erlin1
Product ID
S-KO-05943
Gene Alias
Keo4, Spfh1, 2810439N09Rik
Background
C57BL/6JCya
Gene Full Name
ER lipid raft associated 1
Modification
Conventional knockout
NCBI ID
226144 (Mouse)
Phenotype
MGI:2387613
Chromosome
Chr 19 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000071698
NCBI Transcript ID
NM_001164359
Target Region
Exon 3~6
Size of Effective Region
~10.8 kb
Overview of Gene Research
Erlin1, also known as endoplasmic reticulum lipid raft associated 1, forms complexes with Erlin2 on the endoplasmic reticulum (ER) membrane, creating ring-like cup-shaped structures. These complexes act as platforms to bind cholesterol and E3 ubiquitin ligases, potentially defining functional nanodomains. They are involved in multiple cellular processes, including cholesterol metabolism, the secretory pathway, autophagy, and are associated with neurodegenerative diseases [1,3,5].

In functional studies, Erlin1/2 scaffolds were found to mediate the interaction between TMUB1 and RNF170, and limit cholesterol esterification, thus regulating cholesterol transport from the ER to the Golgi apparatus and the secretory pathway [1]. In autophagy research, knocking down ERLIN1 gene expression impaired the interaction between AMBRA1 and ERLIN1 at mitochondria-associated membranes (MAMs), hindering autophagosome formation [3]. Also, the disruption or deletion of the Erlin1/2 complex reduced phosphatidylinositol 3-phosphate (PI(3)P) levels in HeLa cells, correlating with a decrease in autophagic flux [5]. Mutations in ERLIN1 have been linked to hereditary spastic paraplegia (SPG62), and a series of 13 individuals with biallelic ERLIN1 variants presented with childhood-onset paraparesis, with possible cerebellar and peripheral nerve involvement [2,4]. Additionally, the ERLIN1 p.Ile291Val variant is associated with protection against metabolic dysfunction-associated steatotic liver disease (MASLD) [6].

In conclusion, Erlin1 is crucial for maintaining cellular lipid homeostasis, autophagy regulation, and is significantly associated with neurodegenerative and metabolic diseases. Gene-knockout or conditional-knockout mouse models, if available in the future, could further clarify its role in these biological processes and diseases, providing new insights into potential therapeutic strategies for related disorders.

References:
1. Veronese, Matteo, Kallabis, Sebastian, Kaczmarek, Alexander Tobias, Krüger, Marcus, Rugarli, Elena I. 2024. ERLIN1/2 scaffolds bridge TMUB1 and RNF170 and restrict cholesterol esterification to regulate the secretory pathway. In Life science alliance, 7, . doi:10.26508/lsa.202402620. https://pubmed.ncbi.nlm.nih.gov/38782601/
2. Zhu, Ze-Yu, Li, Zi-Yi, Zhang, Chao, Tian, Wo-Tu, Cao, Li. 2022. A novel homozygous mutation in ERLIN1 gene causing spastic paraplegia 62 and literature review. In European journal of medical genetics, 65, 104608. doi:10.1016/j.ejmg.2022.104608. https://pubmed.ncbi.nlm.nih.gov/36100157/
3. Manganelli, Valeria, Matarrese, Paola, Antonioli, Manuela, Sorice, Maurizio, Garofalo, Tina. 2020. Raft-like lipid microdomains drive autophagy initiation via AMBRA1-ERLIN1 molecular association within MAMs. In Autophagy, 17, 2528-2548. doi:10.1080/15548627.2020.1834207. https://pubmed.ncbi.nlm.nih.gov/33034545/
4. Cogan, Guillaume, Zaki, Maha S, Issa, Mahmoud, de Sainte Agathe, Jean-Madeleine, Mignot, Cyril. 2024. Biallelic variants in ERLIN1: a series of 13 individuals with spastic paraparesis. In Human genetics, 143, 1353-1362. doi:10.1007/s00439-024-02702-0. https://pubmed.ncbi.nlm.nih.gov/39367212/
5. Hua, Fanghui, Bonzerato, Caden G, Keller, Katherine R, Luo, Juntao, Wojcikiewicz, Richard J H. 2024. The erlin1/erlin2 complex binds to and stabilizes phosphatidylinositol 3-phosphate and regulates autophagy. In Biochemical and biophysical research communications, 731, 150397. doi:10.1016/j.bbrc.2024.150397. https://pubmed.ncbi.nlm.nih.gov/39018973/
6. Rendel, Miriam Daphne, Vitali, Cecilia, Creasy, Kate Townsend, Rader, Daniel J, Schneider, Carolin Victoria. 2024. The common p.Ile291Val variant of ERLIN1 enhances TM6SF2 function and is associated with protection against MASLD. In Med (New York, N.Y.), 5, 963-980.e5. doi:10.1016/j.medj.2024.04.010. https://pubmed.ncbi.nlm.nih.gov/38776916/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research